×

Research and Markets: Cancer Stem Cells Drug Pipeline Update 2012 Includes More Than 203 Principal Investigators plus Their Collaborators

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/dsn5rh/cancer_stem_cells) has announced the addition of the "Cancer Stem Cells Drug Pipeline Update 2012" report to their offering.

There are today 203 companies plus partners developing 243 cancer stem cells and developmental pathways drugs in 684 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 123 drugs. Cancer Stem Cells Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 165 different targets. These targets are further categorized on in the software application by 38 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.

Drug Pipeline Update at a Glance

Investigators

Includes more than 203 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators.

Note: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator.

Drug name & Synonyms

Lists commercial, generic and code names for drugs.

Developmental stage

This Drug Pipeline Update contains 243 cancer stem cells and developmental pathways drugs in development, which have a total of 684 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs

Marketed# 15

Registered# 1

Pre-registration# 1

Phase III# 11

Phase II# 56

Phase I# 73

Preclinical# 169

No Data# 3

Suspended# 3

Ceased# 123

Indications

Included cancer stem cells and developmental pathways drugs are also in development for 133 other indications, where of 76 are different cancer indications.

Targets

Identified drugs are linked to more than 165 different targets, divided into 38 classifications of molecular function.

Identified targets are categorized into 28 different primary and alternate sub-cellular localizations.

For more information visit http://www.researchandmarkets.com/research/dsn5rh/cancer_stem_cells

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Source: Research and Markets